Core Viewpoint - EyePoint, Inc. has appointed Michael Campbell as Chief Commercial Officer to lead the commercial strategy and launch readiness for DURAVYU, an investigational treatment for retinal diseases currently in Phase 3 development [1][2] Company Overview - EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for serious retinal diseases, with its lead product candidate DURAVYU expected to provide significant commercial potential [8][9] - The company is headquartered in Watertown, Massachusetts, and has a commercial manufacturing facility in Northbridge, Massachusetts [9] Leadership Appointment - Michael Campbell brings over 30 years of commercial leadership experience, having successfully launched several ophthalmology products, including Lucentis and Xiidra [1][3][4] - His previous roles include Chief Commercial Officer at Opthea and Senior Vice President at Viatris Eye Care, where he led the launch of Tyrvaya [3][4] Product Development - DURAVYU is currently in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), with topline data expected in mid-2026 [8][10] - The product is designed as a sustained delivery treatment combining vorolanib, a selective tyrosine kinase inhibitor, and is positioned to potentially be the first sustained release TKI to market [2][8] Commercial Strategy - The company aims to leverage Campbell's expertise to position DURAVYU for a successful U.S. launch, emphasizing a patient-centric approach and robust clinical data [2][8] - DURAVYU is expected to address both VEGF-mediated vascular leakage and IL-6 mediated inflammatory drivers of DME, enhancing its potential market impact [10]

Core Insights - EyePoint, Inc. is advancing its lead product candidate, DURAVYU, through pivotal Phase 3 trials for wet age-related macular degeneration (AMD) and diabetic macular edema (DME), with significant milestones expected in 2026 [1][2] Company Updates - DURAVYU is positioned as a unique sustained-release treatment for retinal diseases, with pivotal trials for wet AMD on track for data readout starting mid-2026 and first patient dosing for DME expected in Q1 2026 [1][2] - The company reported a successful year in 2025, focusing on scientific rigor and a patient-centric approach, aiming for expedited NDA filing and FDA review for DURAVYU [2][4] - EyePoint completed enrollment of over 900 patients in the Phase 3 trials for wet AMD, making it one of the fastest enrolling programs in this space [4] Product Details - DURAVYU (vorolanib intravitreal insert) is designed for sustained drug delivery, releasing therapeutic doses for at least six months via a simple in-office injection [8][9] - Vorolanib, a tyrosine kinase inhibitor, has shown no ocular safety signals in previous trials and targets both VEGF-mediated vascular permeability and IL-6 mediated inflammation [9][10] - The Phase 3 trials for wet AMD (LUGANO and LUCIA) are designed to demonstrate noninferiority compared to aflibercept, with primary endpoints focused on visual acuity changes [4][11] Financial Position - EyePoint raised $172.5 million in a public offering in October 2025, with approximately $300 million in cash and investments as of December 31, 2025, providing a cash runway into Q4 2027 [11][12] Upcoming Events - The company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, highlighting its advancements and future plans [1][11]